NEW YORK, July 20, 2017 /PRNewswire/ --
If you want a Stock Review on ACAD, ADRO, AGIO, or AVXS then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Today's attention is redirected to the Biotechnology sector, which comprises companies that harness biological processes to create technologies and products
On Wednesday, shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. recorded a trading volume of 1.50 million shares. The stock ended the session 0.14% higher at $29.00. The Company's shares have gained 3.61% in the last one month and 0.55% on an YTD basis. The stock is trading 3.95% above its 50-day moving average. Moreover, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 54.51. The free research report on ACAD is available at:
Shares in Berkeley, California headquartered duro BioTech Inc. recorded a trading volume of 334,011 shares. The stock ended yesterday's trading session 1.13% higher at $13.45. The Company's shares have advanced 28.10% in the past month, 44.62% in the previous three months, and 17.98% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 23.89% and 19.80%, respectively. Furthermore, shares of Aduro BioTech, which focuses on the discovery, development, and commercialization, that transform the treatment of challenging diseases, have an RSI of 77.16.
On July 13th, 2017, Aduro BioTech announced that it has earned a $2.0-million milestone payment under its worldwide licensing agreement with Merck (known as MSD outside the United States and Canada) for work supporting the preparation of an Investigational New Drug Application for its anti-CD27 antibody. The Company is looking forward to working closely with Merck in its effort to advance this promising and novel approach in the field of immunotherapy into clinical development. The complimentary report on ADRO can be downloaded at:
Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc.'s stock closed the day 0.64% higher at $56.39 with a total trading volume of 274,212 shares. The Company's shares have advanced 8.95% in the past month, 15.70% in the previous three months, and 35.13% since the start of this year. The stock is trading 8.38% and 10.98% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Agios Pharma, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 58.13.
On June 24th, 2017, Agios Pharma presented updated data from its wholly owned pyruvate kinase-R activator, demonstrating the potential for the first disease-modifying treatment for patients with pyruvate kinase (PK) deficiency at the 22nd Congress of the European Hematology Association. DRIVE PK is an ongoing global open-label, Phase 2, safety and efficacy trial evaluating AG-348 in adult, transfusion-independent patients with PK deficiency. With data now available from all 52 patients, AG-348 continues to demonstrate clinically relevant and sustained increases in hemoglobin.
On June 26th, 2017, research firm Janney downgraded the Company's stock rating from 'Buy' to 'Neutral'. Visit us today and download our complete research report on AGIO for free at:
Bannockburn, Illinois headquartered AveXis Inc.'s stock finished Wednesday's session 0.69% higher at $83.13 with a total trading volume of 439,017 shares. The Company's shares have advanced 15.41% in the last one month, 8.06% over the previous three months, and 74.17% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.79% and 29.34%, respectively. Additionally, shares of AveXis, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 63.69.
On June 26th, 2017, AveXis announced the closing of its previously announced underwritten public offering of 4,111,250 shares of its common stock at a price to the public of $70.00 per share before underwriting discounts and commissions, including 536,250 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The net proceeds from the offering, after deducting the underwriting discounts and commissions and other offering expenses payable by the Company, are estimated to be approximately $269.8 million. Get free access to your technical report on AVXS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All